Apoptosis involves mitochondrial steps such as the release of the apoptogenic factor cytochrome c which are eectively blocked by Bcl-2. Although Bcl-2 may have a direct action on the mitochondrial membrane, it also resides and functions on the endoplasmic reticulum (ER), and there is increasing evidence for a role of the ER in apoptosis regulation as well. Here we uncover a hitherto unrecognized, apoptotic crosstalk between the ER and mitochondria that is controlled by Bcl-2. After triggering massive ER dilation due to an inhibition of secretion, the drug brefeldin A (BFA) induces the release of cytochrome c from mitochondria in a caspase-8-and Bid-independent manner. This is followed by caspase-3 activation and DNA/nuclear fragmentation. Surprisingly, cytochrome c release by BFA is not only blocked by wild-type Bcl-2 but also by a Bcl-2 variant that is exclusively targeted to the ER (Bcl-2/cb5). Similar ®ndings were obtained with tunicamycin, an agent interfering with N-linked glycosylations in the secretory system. Thus, apoptotic agents perturbing ER functions induce a novel crosstalk between the ER and mitochondria that can be interrupted by ER-based Bcl-2.
Introduction
Apoptosis involves a subset of eector caspase proteases (caspases-3,-6,-7) which dismantle the cell by cleaving structural proteins essential for maintaining nuclear and cytoplasmic architecture and enzymes essential for repair of damaged cell components (NunÄ ez et al., 1998; Stroh and Schulze-Ostho, 1998) . Activation of these caspases occurs via mitochondriaindependent and -dependent mechanisms. In the former case, an adaptor protein such as FADD (Fasassociated death domain) clusters an initiator caspase such as caspase-8 so that the protease can autoactivate and cleave and activate eector caspases (Ashkenazi and Dixit, 1998; Kumar and Colussi, 1999) . In the latter case, some unknown factors or a caspase-8-mediated cleavage and mitochondrial translocation of the Bcl-2 homolog Bid damage mitochondria to release cytochrome c into the cytoplasm (Green and Reed, 1998; Li et al., 1998; Luo et al., 1998) . Cytochrome c then binds to cytoplasmic Apaf-1 which recruits and oligomerizes the initiator caspase-9 for autoactivation and subsequent cleavage and activiation of eector caspases (Hu et al., 1998b; Li et al., 1997; Srinivasula et al., 1998) .
The activation of eector caspases can be blocked by anti-apoptotic members of the Bcl-2 family such as Bcl-2 or Bcl-x L (Adams and Cory, 1998; Reed, 1998) . Both proteins reside on the outer mitochondrial membrane where they prevent the release of cytochrome c in response to many apoptotic stimuli (Kharbanda et al., 1997; Kluck et al., 1997; Yang et al., 1997) . The mechanism of this interference is still unknown. On one hand it was proposed that Bcl-2 and Bcl-x L function as docking proteins (Reed, 1997) , forming multiprotein complexes with apoptosis regulatory molecules including caspase activators such as Apaf-1 (Hu et al., 1998a; Pan et al., 1998) or components of the mitochondrial permeability transition pore such as adenine nucleotide translocator (ANT) or voltagedependent anion channel (VDAC) (Marzo et al., 1998; Shimizu et al., 1999) . On the other hand it was shown that Bcl-x L is structurally homologous to poreforming bacterial toxins (Muchmore et al., 1996) and can form ion channels on membranes in vitro (Minn et al., 1997; Schendel et al., 1998) . Such an activity may maintain the ion homeostasis across the mitochondrial membranes and thus prevent major mitochondrial damage.
However, apart from mitochondria, Bcl-2 and Bcl-x L associate with other cytoplasmic membranes, notably those of the nuclear envelope and the ER (Givol et al., 1994; Krajewski et al., 1993) raising the possibility that they also act at extramitochondrial sites. Indeed, it was recently reported that a Bcl-2 targeted to the ER via the C-terminus of cytochrome b5 was capable of blocking most, albeit not all types of apoptosis (Lee et al., 1999; Zhu et al., 1996) . It has however remained enigmatic how Bcl-2 performs its survival function on the ER.
Studying ER abnormalities during apoptosis has clearly lagged behind that of mitochondria. The ER surveys the correct folding, glycosylation and sorting of the proteins in the secretory system (Aridor and Balch, 1999) . When these processes are perturbed, two signaling pathways can be activated; the unfolded protein response (UPR) pathway leading to the induction of ER chaperones such as grp78/Bip via the C/EBP homologous transcription factor CHOP/ Gadd153 (Chapman et al., 1998; Wang et al., 1996) and the ER overload response (EOR) pathway leading to the production of cytokines via the transcription factor NFkB (Pahl and Baeuerle, 1997) . Both pathways help the cell to cope with incorrectly folded or accumulated proteins in the ER but may also contribute to its elimination when abnormalities become too extensive. Consistent with this idea, both CHOP/Gadd153 (Brenner et al., 1997; Zinszner et al., 1998) and NFkB (Baichwal and Baeuerle, 1997) have been implicated in apoptosis regulation. Moreover, several ER membrane proteins have been reported which interact with Bcl-2 family members such as Bax inhibitor I (Xu and Reed, 1998) , Bap31 (Ng et al., 1997) , calnexin (Torgler et al., 1997) and the calcium pump SERCA (Kuo et al., 1998) although the purpose of these interactions is yet unknown.
Even though we are getting a better picture of the role of ER perturbations in apoptosis induction, we do Figure 1 BFA/CHX provoked dramatic ER dilation. Electron microscopy imaging (magni®cation 55006) of R6 and R6-Bcl-2#9 cells non-treated or treated with BFA/CHX for 6 h. Note that at this time the BFA/CHX-treated cells display a massively vacuolarized ER but no typical signs of apoptosis such as plasma membrane blebbing or nuclear condensation/fragmentation. Scale bar in the lower left corner corresponds to 1 mm not yet know how they impinge on the apoptotic machinery. Here we apply two apoptotic stresses that produce aberrant protein in the secretory system; brefeldin A (BFA), which blocks retrograde transport of Golgi-derived vesicles, leading to a stop in secretion and the fusion of the Golgi/ER compartments (Chardin and McCormick, 1999; Fujiwara et al., 1998) and tunicamycin which inhibits the ®rst reaction in the dolichol pathway of N-glycosylations of proteins in the ER lumen (Olden et al., 1982; Tkacz and Lampen, 1975) . Interestingly, both stresses provoke a release of cytochrome c before or at the time of eector caspase-3 activation suggesting a crosstalk between the perturbed ER and mitochondria. This crosstalk does not involve caspase-8 mediated cleavage and/or mitochondrial translocation of Bid, but a yet unknown, caspase-independent mechanism. Moreover, Bcl-2 can interrupt this crosstalk at the level of the ER and does not need to be associated with mitochondria to ful®ll its function.
Results
When applied to various cell types in dierent doses, BFA induced rapid cell death that was not clearly apoptotic and dicult to monitor biochemically (data not shown). This was probably due to the massive accumulation of aberrant proteins in the collapsed Golgi-ER hybrid compartment. We therefore diminished the amount of aberrant proteins by slowing down their synthesis and subsequent transport into the ER lumen using a low dose of cycloheximide (1 mg/ml) (CHX) in combination with BFA. This dose of CHX alone did not induce apoptosis within the time frame of our experiments (data not shown).
Electron microscopy analysis showed that while healthy, untreated rat embryo ®broblasts (R6 cells) contained only few and small vacuoles, their treatment with 5 mg/ml BFA and 1 mg/ml CHX led to a dramatic vacuolarization of the ER/Golgi network (Figure 1 ). This eect became visible between 4 ± 6 h of the drug treatment, at a time when the cells were still viable ( Figure 2a ) and did not display typical signs of apoptosis such as nuclear condensation (Figure 1 ) or DNA fragmentation (Figure 2b) . However, after 6 h of BFA/CHX-treatment, the cells gradually died ( Figure  2a ) and accumulated nucleosome-sized DNA fragments (Figure 2b) . At 24 h posttreatment, up to 70% of the cells were shrunken and had condensed and/or fragmented nuclei (Figure 3a ). In the presence of a ®vefold excess of Bcl-2 (R6-Bcl-2#9), BFA/CHX still provoked massive ER dilation as compared to untreated cells (Figure 1 ), but cell shrinkage ( Figure  3a ) and DNA/nuclear fragmentation (Figures 2b and  3a) were eectively blocked, and cell survival was prolonged (Figure 2a ). Similar ®ndings were obtained when R6 cells were exposed to tunicamycin (Figure 2a and data not shown). These data show that ER damaging agents kill cells by apoptosis, and that Bcl-2 prevents the killing at a step distal to the damage.
To uncover how the perturbed ER communicates with the apoptotic machinery, we ®rst determined the activation of the eector caspase-3. For that purpose, we subjected BFA/CHX-treated cells to immuno¯uor-escence analysis using an antibody speci®c for the active p17 form of caspase-3. In addition, we prepared from these cells a cytosolic extract to detect p17 on Western blots and to measure the respective caspase activity with the¯uorogenic substrate DEVD-AMC
While there was a low anti-p17 immuno¯uorescence staining of untreated R6 cells, a 24 h treatment with BFA/CHX led to a strong diuse staining indicating the presence of active p17 in the cytoplasm and probably the nucleus (Figure 3a) . Moreover, the cytosolic extract of BFA/CHX-treated cells had almost all p32 caspase-3 precursor converted into the active p17 form (Figure 3b ) and displayed a strong activity towards the DEVD-AMC substrate (Figure 3c ). Importantly, both the formation of p17 caspase-3 (data not shown) and its associated DEVDase activity were not signi®cantly detected before 10 h of BFA/ CHX treatment ( Figure 3c ) indicating that they were a consequence rather than a cause of ER dilation. BFA/ CHX-treated R6-Bcl-2#9 cells neither showed anti-p17 immuno¯uorescence staining (Figure 3a) , nor the formation of the p17 protein (Figure 3b ) or DEVDase activity (Figure 3c ) in the cytoplasm at any time of the stress period. The treatment of R6 cells with tunicamycin resulted in a similar degree of caspase-3 activation that was fully blockable by Bcl-2 ( Figure  4a ). Thus, Bcl-2 protected cells from BFA/CHX-or tunicamycin-induced apoptosis at a step between the ER stress and caspase-3 activation.
We next tested whether BFA/CHX or tunicamycin employed the release of cytochrome c to activate caspase-3. In the absence of drug treatment, cytochrome c was immunodetected in elongated,`spaghetti'-likestructures typical for mitochondria in adherent R6 cells (Figure 3a ). This pattern changed to a strong, diuse staining when the cells were treated with BFA/CHX indicating that cytochrome c was released to the cytoplasm (Figure 3a) . Because cytochrome c release and caspase-3 activation occurred almost simultaneously, it was dicult to determine the exact order of events of apoptotic signaling. Western blot analysis con®rmed that, in response to BFA/CHX, cytochrome c appeared in the cytoplasm almost at the same time as the generation of active p17 caspase-3 (data not shown) and its associated DEVDase activity (compare Figure 3c and  d) . A similar ®nding was obtained with tunicamycin ( Figure 4a,b) . These data suggest that cytochrome c release is a signaling event between the damaged ER and caspase-3 activation in BFA/CHX-and tunicamycininduced apoptosis. As Bcl-2 associates with mitochondrial membranes and blocks the release of cytochrome c by many apoptotic agents, it was not surprising that R6-Bcl-2#9 cells had cytochrome c retained in a`spaghetti'-like pattern ( Figure 3a ) and did not show detectable cytosolic cytochrome c on Western blots at any time point of the BFA/CHX or tunicamycin treatments (Figures 3d and 4b) .
As Bcl-2 is widely distributed throughout the cell (Krajewski et al., 1993) we wanted to know which subcellular form was responsible for interfering with cytochrome c release. Immuno¯uorescence analysis of R6-Bcl-2#9 cells revealed a strong immunostaining of Bcl-2 on the nuclear envelope and its associated endoplasmic network (Figure 5a ). This staining was not changed when the cells were treated with BFA/ CHX so that Bcl-2 stained around the vacuolarized ER (Figure 5a ). To con®rm the predominant association of Bcl-2 with the nuclear/ER network, we performed Western blots on subcellular fractions from the R6-Bcl-2#9 cell line. These fractions were up to 90% pure as determined by antibodies against organelle-speci®c marker proteins (lamin B1 for nuclei, cytochrome c oxidase (COX) for mitochondria, calnexin for ER and Lamp-1 for lysosomes) ( Figure  5b ). As shown in Figure 5b , most of the Bcl-2 was found in nuclear and microsomal/ER fractions although it was also present on mitochondria and other membranes. Again, the treatment of R6-Bcl-2#9 cells with BFA/CHX did not much change this subcellular distribution of Bcl-2 (Figure 5b) . To see whether ER-bound Bcl-2 could interfere with cytochrome c release and caspase-3 activation, we generated a version of Bcl-2 that had its C-terminus exchanged for that of cytochrome b5. Such a Bcl-2/ cb5 chimera had previously been shown to target the ER membrane and to block apoptosis in certain, but not all cells (Lee et al., 1999; Zhu et al., 1996) . A stable R6 cell line overexpressing Bcl-2/cb5 (R6-Bcl-2/ cb5#6) showed the same nuclear/ER immuno¯uores-cence staining as R6-Bcl-2#9 cells (Figure 5a) . However, the chimeric protein was absent from mitochondria and exclusively present in nuclear and microsomal/ER fractions (Figure 5b) . When compared to wild-type Bcl-2, Bcl-2/cb5 was as eective in interfering with BFA/CHX-or tunicamycin-induced caspase-3 activation (Figures 3a ± c and 4a ), cell shrinkage and nuclear condensation/fragmentation (Figure 3a ) and cell death (Figure 2a ). This could be shown for multiple cell lines of the same genotype (data not shown). Surprisingly, Bcl-2/cb5 did also fully impede BFA/CHX-or tunicamycin-induced cytochrome c release. Neither by immuno¯uorescence (Figure 3a) nor by Western blotting (Figures 3d and  4b ) did we see any appearance of cytosolic cytochrome c in R6-Bcl-2/cb5#6 cells treated with these ER damaging agents. These ®ndings suggest that Bcl-2 can function on the ER to inhibit an ER damageinduced mitochondrial event. Interestingly, the deathprotective eect of Bcl-2/cb5 was not limited to ER stress agents but also evident (although less pronounced) for apoptotic stimuli such as staurosporine that are known to act through mitochondrial damage (Figure 2a) (Kluck et al., 1997) . Figure 5 Subcellular localization of wild-type Bcl-2 and ER-targeted Bcl-2/cb5 in untreated and BFA/CHX-treated R6 cells. (a) Anti-Bcl-2 (27-6) immuno¯uorescence analysis of ®xed/permeabilized R6-Bcl-2#9 and R6-Bcl-2/cb5#6 cells before and after the treatment with BFA/CHX for 24 h. (b) Anti-Bcl-2 (27-6) immunoblot analysis of subcellular fractions from untreated and BFA/ CHX-treated R6-Bcl-2#9 and R6-Bcl-2/cb5#6 cells. The fractions were prepared by sucrose gradient centrifugation and tested for their purity using antibodies against COX (mitochondria), lamin B1 (nuclei), lamp-1 (lysosomes) or calnexin (ER/microsomes) as described in Materials and methods It has been previously shown that cytochrome c release may be triggered by the activation of the initiator caspase-8 which cleaves the Bcl-2 family member Bid to allow its translocation from the cytoplasm to the mitochondrial membrane (Li et al., 1998; Luo et al., 1998) . We therefore examined whether BFA/CHX or tunicamycin used such a pathway to crosstalk with mitochondria. A treatment of JILY B lymphoblasts with anti-CD95 antibodies for 6 h led to a signi®cant increase in cytosolic caspase-8 activity (IETDase activity) (Figure 6a ) as well as the cleavage of p24 Bid into its 15 kD fragment and the translocation of both proteins to the mitochondrial membrane (Figure 6b) . However, neither BFA/CHX nor tunicamycin provoked any major activation of caspase-8 (Figure 6a ) or proteolysis/mitochondrial translocation of Bid ( Figure  6b ) over a time period of 24 h in R6 cells. Moreover, cytochrome c release induced by both BFA/CHX (data not shown) or tunicamycin (Figure 4b ) was not blocked in the presence of the general caspase inhibitor Z-VAD.fmk (Z-Val-Ala-Asp.¯uoromethylketone) (data not shown) indicating that none of the known caspases were involved in conveying stress signals from the damaged ER to mitochondria. Thus, the ER-mitochondria crosstalk in response to BFA/CHX or tunicamycin involves a novel, caspase-independent signaling pathway.
Discussion
How can a damage in the ER compartment be translated into an apoptotic response that involves the release of cytochrome c from mitochondria? As the caspase-8/Bidmediated pathway does not seem to play a role, we propose alternative ways of crosstalks. One possibility is that the ER and mitochondria communicate via membranes as they can be in close contact and easily exchange lipids, calcium and glycoproteins (Chandra et al., 1998; Rizzuto et al., 1998) . A possible mediator may be the sphingolipid ceramide which is generated by sphingomyelin hydrolysis in response to various apoptotic stimuli (Kolesnick and KroÈ nke, 1998) , including BFA (Linardic et al., 1996) and has recently been shown to directly act on mitochondria to stimulate cytochrome c release (Ghafourifar et al., 1999) . We have found that BFA/CHX indeed provoked ceramide production in R6 cells that preceded cytochrome c release (data not shown), but due to the lack of appropriate agents that block ceramide signaling we cannot yet say whether this lipid is required for BFA-induced apoptosis. In addition, it has been disputed whether ceramide plays any role in apoptosis induction (Hofmann and Dixit, 1999) . Alternatively, an ER-mitochondrial crosstalk could be mediated via yet unidenti®ed proteins that are either released from the damaged ER lumen due to an increased membrane permeability or cleaved from the ER membrane by a caspase-independent mechanism. Finally, such a crosstalk may involve components of the unfolded protein (UPR) and ER overload (EOR) response pathways (Pahl and Baeuerle, 1995) . The transcription factor CHOP/Gadd153, a component of the UPR pathway, has been shown to mediate apoptosis triggered by tunicamycin (Brenner et al., 1997; Olden et al., 1982; Zinszner et al., 1998) . CHOP-regulated genes relevant for apoptosis regulation have not yet been identi®ed but may include pro-apoptotic molecules such as the Bcl-2 family member Bax, a known trigger of cytochrome c release on mitochondria (RosseÂ et al., 1998) . On the other hand, it is known that activation of the transcription factor NF-kB via the EOR involves reactive oxygen species (ROS) which are produced from the oxidizing environment of the ER lumen and the action of cytochrome p450 on the ER membrane (Pahl and Baeuerle, 1997; Schreck et al., 1992) . ROS can mount an oxidative stress that damages membranes, including those of mitochondria (Kowaltowski and Vercesi, 1999) . Indeed, preliminary data from our laboratory show that antioxidants such as N-acetylcysteine or pyrrolidine dithiocarbamate (PDTC) can partially protect R6 cells from BFA/CHX-induced cytochrome c release and apoptosis (data not shown).
It has previously been reported that Bcl-2 prevents BFA-induced apoptosis (Guo et al., 1998; Olivier et al., 1997) , but its mode and intracellular site of action have not yet been unveiled. Here we show that BFA or tunicamycin induces mitochondrial cytochrome c release and caspase-3 activation which are both blocked by a version of Bcl-2 targeted to the ER. How could Bcl-2 control mitochondrial events from the ER membrane? Again, the simplest explanation would have been that Bcl-2 sequesters Bid away from its mitochondrial action as the two proteins are known to interact. However, based on our results here, other processes are likely to occur. First, Bcl-2 may bind to and/or neutralize potentially pro-apoptotic ER components such as Bap31 (Ng et al., 1997) or yet unknown ceramide targets. Second, Bcl-2 may interfere with the generation or action of ROS as it has been shown to function as an antioxidant (Hockenberry et al., 1993) . Third, Bcl-2 may modulate ER membrane permeability by either forming an ion channel or regulating ERbased channels or pumps such as the IP 3 -receptor calcium channel or the Ca 2+ ATPase pump (SERCA) (Berridge et al., 1998) . Bcl-2 can interact with SERCA and either maintain calcium uptake into the ER or reduce calcium eux of the ER in cells treated with the SERCA inhibitor thapsigargin (Kuo et al., 1998; He et al., 1997) . Finally, we propose that Bcl-2 may act on any intracellular membrane to sequester yet unknown cytoplasmic activators of cytochrome c release. Thus, a Bcl-2 targeted to lysosomal or plasma membranes should retain such an activity, a possibility which we are currently testing. The present study however already shows that Bcl-2 does not need to associate with mitochondria to exert a cytochrome c release inhibiting function. Thus, it cannot be the sole role of Bcl-2 to bind and regulate mitochondria-speci®c proteins such as VDAC (Shimizu et al., 1999) or ANT (Marzo et al., 1998) or to directly form ion channels in the mitochondrial membrane as recently proposed (Schendel et al., 1997) . Our cellular system using BFA/CHX or tunicamycin and ER-targeted Bcl-2 will help us to isolate other targets of Bcl-2 and delineate a novel ER/mitochondrial crosstalk pathway for apoptosis induction.
Materials and methods

Cell lines and treatments
Rat 6 (R6) embryo ®broblasts expressing the retroviral vector pMV12 (controls) or the vector containing mouse Bcl-2 (R6-Bcl-2#9) were generated and cultured as previously described (Borner, 1996) . R6 derivatives expressing the ER-targeted Bcl-2/cb5 were produced by transfecting the Bcl-2/cb5/ pcDNA3 plasmid in the presence of Superfect (Qiagen) followed by antibiotic selection on 400 mg/ml geneticin (G418) (Life Technologies). A clone expressing Bcl-2/cb5 to similar levels as wild-type Bcl-2 in R6-Bcl-2#9 was used for further studies (R6-Bcl-2/cb5#6). The various cell lines were either treated with 5 mg/ml BFA and 1 mg/ml CHX or 5 mg/ ml tunicamycin (all Sigma) or 250 nM staurosporine in the presence or absence of 100 mM of the general caspase inhibitor ZVAD.fmk (Bachem). Human JILY B lymphoblasts were cultured as described (Borner, 1996) and exposed to 100 ng/ml anti-CD95 antibody (anti-APO-1, IgG3, kindly provided by P Krammer, Heidelberg, Germany) where indicated.
Generation of ER-targeted Bcl-2/cb5
To create the Bcl-2/cb5 fusion gene, we ampli®ed by polymerase chain reaction (PCR) the DNA fragment corresponding to the hydrophobic C-terminus of rat cytochrome b5 (aa 100 ± 134) (cDNA kindly provided by Stephen Sligar, Urbana, USA and Nica Borgese, Milano, Italy) by using a 5' primer with an introduced SphI site (for subcloning into the site corresponding to Met203 of mouse Bcl-2) and a 3' PCR primer with an introduced XbaI site (for subcloning into the multiple cloning site of Bcl-2/pcDNA3). The ampli®ed fragment was puri®ed by Jetsorb (Genomed), cut with SphI and XbaI and ligated into the corresponding sites of Bcl-2/pcDNA3 yielding the Bcl-2/cb5/pcDNA3 plasmid. The corresponding ligation product was tested for the correct reading frame by DNA sequencing (Microsynth).
Survival/apoptosis assays
To estimate cell survival, the various cells were trypsinized and mixed with 0.2% (w/v) of the Trypan blue dye. Cells were counted on 20 ®elds in a Neubauer chamber and the proportion of white (live) to total cells determined. The experiments were repeated at least three times. Genomic DNA fragmentation was tested on 2% agarose gels as previously described (RosseÂ et al., 1998) .
Subcellular fractionation
The various R6 cell derivatives were washed twice in PBS and once in extraction buer STE (10 mM HEPES, pH 7.4, 1 mM EDTA, 0.25 M sucrose, 2 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, 1 mg/ml pepstatin) followed by scraping into STE and lysing in a tight-®tting Dounce homogenizer with 20 ± 30 strokes. The extract was inspected under the microscope and only processed further when 90% of the cells were lysed. The homogenate was then applied to a linear gradient of sucrose (0.73 ± 1.9 M) and centrifuged at 20 000 g for 1 h. The banded organelles were recovered by syringe, diluted with an equal volume of 10 mM HEPES buer and sedimented by centrifugation at the speed appropriate for the respective organelles. The purity of the organelles was determined on Western blots using antibodies against speci®c organelle markers (lamin B1 for nuclei, COX for mitochondria, lamp-1 for lysosomes/peroxisomes, calnexin for microsomes/ER). For the preparation of cytosols (anti-cytochrome c and anti-caspase-3 immunoblots) the homogenate was precentrifuged at 750 g for 10 min to remove nuclei and unbroken cells followed by a centrifugation at 100 000 g for 1 h to clear o the membranes.
Western blotting
30 ± 50 mg of protein was subjected to 12 ± 15% SDS ± PAGE followed by blotting to a PVDF membrane as previously described (Borner et al., 1994) . The membrane was blocked in 3% milk and incubated with either mouse monoclonal anticytochrome c (1 : 1000) (clone 7H8.2C12, Pharmingen), rabbit polyclonal anti-caspase-3 (1 : 10 000) (generous gift of D Nicholson, Merck-Frosst, Quebec, Canada), rabbit polyclonal anti-Bcl-2 (27-6, 1 : 5000) (Borner et al., 1994) , mouse monoclonal anti-cytochrome c oxidase subunit VIc (COX) (1 : 1000) (Molecular Probes), mouse monoclonal anti-lamin B1, clone L-5 (1 : 1000) (Zymed), mouse monoclonal anti-rat Lamp-1 (1 : 5000) (generous gift of W Hunziker, University of Lausanne, Switzerland), mouse monoclonal anti-calnexin (1 : 2000) (Transduction Laboratories), or goat polyclonal anti-Bid (1 : 1000) (R&D Systems) followed by peroxidasecoupled anti-mouse, anti-goat or anti-rabbit secondary antibodies (1 : 5000) (Jackson Laboratories) and detection by enhanced chemiluminescence (Socochim, Pierce).
Caspase assays
Caspase-3 and caspase-8 activities were measured in the cytosol using the¯uorogenic peptide substrates DEVD-AMC and IETD-AMC, respectively. Brie¯y, cytosol was prepared from untreated and BFA/CHX-or tunicamycin treated R6 cell derivatives by four cycles of freeze-thawing (7808/258C) in buer A (25 mM HEPES/KOH, pH 7.4, 2 mM EGTA, 2 mM MgCl 2 , 2 mM DTT, 5 mg/ml cytochalasin B, 100 mM PMSF, 25 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mg/ml pepstatin) followed by ultracentrifugation at 100 000 g. 10 ml of cytosol (100 ± 300 mg protein) was mixed with 90 ml of assay buer (100 mM HEPES, pH 7.5, 2 mM DTT) and 1 ml of a 6 mM solution of the DEVD-AMC or IETD-AMC peptide substrates (Alexis). The speci®c liberation of AMC from these peptides was monitored during 30 min in blackcoated 96 well microtiter plates (Nunc) using a Lambdā uoro FL600 microplate¯uorescence reader (MWG Biotech) and 360-nm excitation and 460-nm emission wavelengths. Quantitation was performed using the KC-4 program developed by MWG Biotech.
Immunofluorescence analysis A modi®ed protocol described by RosseÂ et al. (1998) was used. Brie¯y, the cells were seeded onto 12 mm glass coverslips at a denstiy of 2610 4 cells/ml. On the next day, the cells were exposed to 5 mg/ml BFA and 1 mg/ml CHX and kept for 24 h at 378C. The coverslips were removed from the medium without washing (in order not to lose slightly detached cells) and directly placed in 4% paraformaldehyde for 10 min (®xation), followed by washing in PBS and treatments with 0.05% saponin for 5 min and acetone for 10 min (permeabilization). After washing in PBS the cells were incubated with mouse monoclonal anti-cytochrome c (clone 6H2.B4, 1 : 50), rabbit polyclonal anti-active p17 caspase-3 antibodies (1 : 1000) (both Pharmingen), or polyclonal anti-Bcl-2 (27-6, 1 : 200) for 90 min followed by secondary Texas-Red conjugated goat anti-mouse and uorescein-conjugated goat anti-rabbit antibodies (both 1 : 75) (Jackson Laboratories). The cells were then post®xed for 10 min in 4% paraformaldehyde containing 2 mg/ml of the Hoechst 33342 stain (Molecular Probes), washed and treated with Slow Fade (Molecular Probes) to prevent fading. The coverslips were viewed under an Axiovert¯uorescence microscope (Zeiss) and pictures taken with a Contax 167 MT camera at magni®cation of 10006.
Electron microscopy
Adherent R6 cells were washed in phosphate buer (0.1 M phosphate, pH 7.2), ®xed in 2.5% glutaraldehyde at 48C for 30 min and post®xed in 1% OsO 4 at room temperature for 20 min. The cells were then dehydrated with increasing concentrations of alcohol (30, 50, 70% plus 1% uranylacetate, 80, 95, 100%), embedded in a mixture of Epon/alcohol (1 : 3 for 15 min, 1 : 2 for 30 min, 3 : 1 for 30 min and pure Epon for 2630 min) and polymerized at 608C for 2 days. The solidi®ed blocks were cut into slices of 50 ± 60 nm thickness. These slices were contrasted in 5% uranylacetate as well as in Reynolds solution (80 mM Pb(NO 3 ) 2 , 120 mM sodium citrate, 160 mM NaOH) and then viewed under the electron microscope.
